Split.It is the base product of Stuttgart start ups, which implemented the Central steps of automated cell culture with a fraction of the hitherto necessary effort. “Currently we are still looking for first-time users for Split.It. From summer 2012 the standard product will be available on the market “, so Roland Huchler, Managing Director of InnoCyte. The low complexity of the technology allows for a completely new design: Split.It is as Benchtop device offered compared to the robotics solutions, small and “handy”is and can be mounted on a table. Especially for medium-sized Biotechnology companies and research labs at universities and hospitals is attractive Split.It, due to the significantly lower cost factor and easier manageable and lower system. The Fraunhofer-Gesellschaft is involved in the InnoCyte GmbH was founded in June 2011 Fraunhofer venture. The reasons for this are obvious. The InnoCyte GmbH has a profound knowledge of the industry in the field of cell culture, as well as the engineering know-how, to develop new solutions for the industry.
For this reason, will place the InnoCyte on this market successfully to, Matthias Keckl, responsible supervisor of InnoCyte at Fraunhofer venture, is convinced. In the coming years, InnoCyte will first address the 2 500 cell culture laboratories in Germany. For the future, the Fraunhofer spin-off plans to tap the European and North American markets. The founder of Stuttgart work concurrently on other products for automated cell culture, which complement the features of Split.It. About InnoCyte basis for the business idea of the Stuttgart-based InnoCyte GmbH is a patent-pending technology, the the central process of the passage realized the automated cell culture with a fraction of the hitherto necessary effort. In June 2011 with support of Fraunhofer venture founded, develops and markets the InnoCyte a family of devices around the automated cell culture. The founding team, consisting of the managing directors Dipl.-ing.
Roland Huchler, the head of application and marketing, Dr. Michael Fritsche, and Dipl.-ing. Dirk Malthan, advisory, has developed in particular the core process of cell culture passage and already at the Fraunhofer Institute for manufacturing engineering and automation for the production of biological cells developed IPA device solutions. The Fraunhofer-Gesellschaft is involved in the InnoCyte of Fraunhofer venture with 25%. Contact: Jorg Rothlingshofer factum press and public relations Schon Strasse 110a 81543 Munich + 49 89 51 91 96 31